---
figid: PMC10892755__pharmaceutics-16-00214-g001
figtitle: Cholesterol and isoprenoid synthesis pathway illustrating how statins inhibit
  the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10892755
filename: PMC10892755__pharmaceutics-16-00214-g001.jpg
figlink: /pmc/articles/PMC10892755/figure/F1
number: F1
caption: Cholesterol and isoprenoid synthesis pathway illustrating how statins inhibit
  the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Created with
  BioRender.com. Accessed on 4 October 2023
papertitle: Potential Benefits and Risks Associated with the Use of Statins
reftext: Nisha Khatiwada, et al. Pharmaceutics. 2024 Feb;16(2).
year: '2024'
doi: 10.3390/pharmaceutics16020214
journal_title: Pharmaceutics
journal_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords: statin | pleiotropic effects | statin-associated symptoms
automl_pathway: 0.8485065
figid_alias: PMC10892755__F1
figtype: Figure
redirect_from: /figures/PMC10892755__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10892755__pharmaceutics-16-00214-g001.html
  '@type': Dataset
  description: Cholesterol and isoprenoid synthesis pathway illustrating how statins
    inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase.
    Created with BioRender.com. Accessed on 4 October 2023
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RHOA
  - NOS3
  - ENO4
  - RAC1
  - RNASE1
  - MAP3K1
  - MAP3K2
  - MAP3K3
  - MAP3K4
  - MAP3K5
  - MAP3K6
  - MAP3K7
  - MAP3K8
  - MAP3K9
  - MAP3K10
  - MAP3K11
  - MAP3K12
  - MAP3K13
  - MAP3K14
  - MAP3K15
  - MAP3K19
  - MAP3K20
  - MAP3K21
  - ARAF
  - BRAF
  - RAF1
  - TAOK1
  - TAOK2
  - TAOK3
  - PAK1
  - PAK2
  - PAK3
  - PAK4
  - PAK5
  - PAK6
  - CDC42
  - Cholesterol
  - Squalene
  - Statins
---
